Nykode Therapeutics AS Ordinary Shares NYKD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYKD is a good fit for your portfolio.
News
-
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting
-
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
-
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
-
Nykode Therapeutics - Quarterly report Q1 2024
Trading Information
- Previous Close Price
- NOK 14.07
- Day Range
- NOK 13.94–14.66
- 52-Week Range
- NOK 12.38–30.18
- Bid/Ask
- NOK 13.88 / NOK 14.70
- Market Cap
- NOK 4.78 Bil
- Volume/Avg
- 940,772 / 789,320
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 40.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 176
- Website
- https://www.nykode.com
Comparables
Valuation
|
Metric
|
NYKD
|
ITOS
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.79 | 1.11 | 2.04 |
Price/Sales | 40.25 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
NYKD
ITOS
CGEM
Financial Strength
|
Metric
|
NYKD
|
ITOS
|
CGEM
|
|---|---|---|---|
Quick Ratio | 8.43 | 12.80 | 19.75 |
Current Ratio | 8.43 | 13.51 | 20.33 |
Interest Coverage | — | — | — |
Quick Ratio
NYKD
ITOS
CGEM
Profitability
|
Metric
|
NYKD
|
ITOS
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | −18.26% | −16.56% | −21.39% |
Return on Equity (Normalized) | −23.64% | −18.86% | −22.60% |
Return on Invested Capital (Normalized) | −26.98% | −22.78% | −26.73% |
Return on Assets
NYKD
ITOS
CGEM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Xhxgrnkppk | Jpqc | $570.2 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bwlztjkj | Twvzkwh | $127.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dhsmrrdj | Wbxnkjl | $117.3 Bil | |||
| Moderna Inc
MRNA
| Gqklxmz | Dhmr | $46.1 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Csfsyrl | Dpqcvd | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Zsrthzmwd | Wpv | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Pghjjyjrk | Ltj | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rjdxtgyv | Ntjtr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Dvrjhfx | Sqmfl | $14.9 Bil | |||
| Incyte Corp
INCY
| Vrlxryvr | Qlcwp | $13.5 Bil |